Article
Medicine, General & Internal
Jeffrey S. Heier, Arshad M. Khanani, Carlos Quezada Ruiz, Karen Basu, Philip J. Ferrone, Christopher Brittain, Marta S. Figueroa, Hugh Lin, Frank G. Holz, Vaibhavi Patel, Timothy Y. Y. Lai, David Silverman, Carl Regillo, Balakumar Swaminathan, Francesco Viola, Chui Ming Gemmy Cheung, Tien Y. Wong
Summary: The primary results of two Phase 3 trials show that faricimab can effectively improve visual acuity for patients with nAMD at intervals of up to 16 weeks, with comparable safety profile to aflibercept. This suggests that faricimab has the potential to reduce treatment burden by extending the time between injections while maintaining efficacy.
Article
Dermatology
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, Ruquan You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe
Summary: Secukinumab 300 mg every 2 weeks demonstrated superior and sustained efficacy compared with every 4 weeks in patients with moderate-to-severe plaque psoriasis who had a higher bodyweight. Uptitration to the every 2 weeks regimen provided additional benefits for nonresponders.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Ophthalmology
Masahiko Shimura, Shigehiko Kitano, Nahoko Ogata, Yoshinori Mitamura, Hideyasu Oh, Haruka Ochi, Shino Ohsawa, Akito Hirakata, YOSEMITE Investigator, RHINE Investigator
Summary: The purpose of this study was to evaluate the efficacy, durability, and safety of Faricimab in Japanese patients with diabetic macular edema (DME). The results showed that Faricimab had similar efficacy and safety in Japanese patients and offered durable vision improvement and improved outcomes for macular edema.
JAPANESE JOURNAL OF OPHTHALMOLOGY
(2023)
Review
Oncology
Carsten Bokemeyer, Fortunato Ciardiello, Olivier Dubreuil, Joel Guigay, Stefan Kasper, Per Pfeiffer, Carmine Pinto, Kensei Yamaguchi, Takayuki Yoshino, Christoph Zielinski, Regina Esser, Josep Tabernero
Summary: The every 2 weeks dosing schedule of cetuximab has been approved for use in patients with colorectal cancer and head and neck cancer. Studies have shown similar clinical benefits and side effects compared to the weekly dosing schedule, making it a convenient alternative.
Article
Ophthalmology
Susumu Ishida, Shih-Jen Chen, Toshinori Murata, Yuichiro Ogura, Paisan Ruamviboonsuk, Taiji Sakamoto, Tachie Fujita, Mika Kawano, Shino Ohsawa, Francis Abreu, Zdenka Haskova, Jane Ives, David Silverman, Young Hee Yoon, YOSEMITE RHINE Investigators
Summary: This study assessed the 1-year efficacy, durability, and safety of Faricimab in Asian and non-Asian patients with diabetic macular edema. The results showed similar outcomes and good tolerability of Faricimab in both Asian and non-Asian subgroups. These data support the use of Faricimab for treating Asian patients with diabetic macular edema.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Oncology
Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Li Zhu
Summary: A benefit:risk assessment was conducted using modeling and simulation of clinical trial data to evaluate the less-frequent dosing regimen of nivolumab and cabozantinib. The results showed comparable efficacy and safety between different dosing regimens.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Nobuyuki Katakami, Takashi Nishimura, Yu Hidaka, Akito Hata, Kazumi Nishino, Masahide Mori, Tomonori Hirashima, Naoto Takase, Toshihiko Kaneda, Hisashi Ohnishi, Satoshi Morita, Yukimasa Hatachi
Summary: The optimal dosing interval of Zoledronic acid (ZA) for lung cancer patients with bone metastases is uncertain. However, this study found that an eight-week ZA interval does not increase the risk of skeletal-related events in these patients.
Article
Ophthalmology
Nicole Eter, Rishi P. Singh, Francis Abreu, Kemal Asik, Karen Basu, Caroline Baumal, Andrew Chang, Karl G. Csaky, Zdenka Haskova, Hugh Lin, Carlos Quezada Ruiz, Paisan Ruamviboonsuk, David Silverman, Charles C. Wykoff, Jeffrey R. Willis
Summary: Faricimab is a novel bispecific antibody with high affinities for both VEGF and angiopoietin-2. By targeting angiogenic factors and inflammatory pathways in addition to the VEGF pathway, it aims to improve treatment outcomes for patients with diabetic macular edema. The YOSEMITE and RHINE trials assess the efficacy, safety, and durability of faricimab compared with aflibercept, using a personalized treatment interval (PTI) approach to address variations in treatment response.
OPHTHALMOLOGY SCIENCE
(2022)
Article
Ophthalmology
Ryusaburo Mori, Shigeru Honda, Fumi Gomi, Akitaka Tsujikawa, Hideki Koizumi, Haruka Ochi, Shino Ohsawa, Annabelle Ayame Okada
Summary: This article evaluated the 1-year efficacy, durability, and safety of faricimab compared to aflibercept in patients with neovascular age-related macular degeneration (nAMD) in the Japan subgroup of the TENAYA trial. The study showed that both faricimab and aflibercept had similar improvements in best-corrected visual acuity (BCVA) with adjusted mean BCVA changes of +7.1 and +7.7 letters, respectively. The use of faricimab every 16 weeks in the Japanese patients demonstrated sustained efficacy and an acceptable safety profile.
JAPANESE JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Adrian Robert Hunt, Vuong Nguyen, Jennifer J. Arnold, Ian L. McAllister, Hemal Mehta, Alessandro Invernizzi, Theodorus Ponsioen, Pierre-Henry Gabrielle, Louise O'Toole, Pavol Kusenda, Socorro Alforja, Daniel Barthelmes, Mark C. Gillies
Summary: This observational study compared the baseline characteristics and 12-month outcomes of treatment-naive HRVO, BRVO, and CRVO eyes treated with VEGF inhibitors. The results showed that HRVO eyes had the greatest improvement in visual acuity compared to BRVO and CRVO eyes. Despite starting closer to CRVO, HRVO eyes achieved similar 12-month visual acuity and CST outcomes to BRVO.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Sanjeeb Bhandari, Vuong Nguyen, Adrian Hunt, Pierre-Henry Gabrielle, Francesco Viola, Hemal Mehta, Les Manning, David Squirrell, Jennifer Arnold, Ian L. McAllister, Daniel Barthelmes, Mark Gillies
Summary: This study aims to analyze the changes in clinical outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO) over time. The results show that the visual acuity and treatment patterns remained stable from 2015 to 2019 for patients with these eye diseases.
Letter
Ophthalmology
Beatrice Gallo, James S. Talks, Ranjeet J. Pandit, Andrew C. Browning
Summary: This case report describes the occurrence of MEWDS and choroidal neovascularization in a patient with cutaneous melanoma on BRAF and MEK inhibitors after COVID-19 infection, followed by partial vision recovery with anti-VEGF treatment.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Claudia Farinha, Patricia Barreto, Rita Coimbra, Maria Luz Cachulo, Joana Barbosa Melo, Jose Cunha-Vaz, Yara Lechanteur, Carel B. Hoyng, Rufino Silva
Summary: This study found that both common and rare genetic variants are associated with AMD, with a rare CFH variant conferring the highest risk of the disease. However, the allele frequency of three major risk variants is lower than expected in the population studied.
ACTA OPHTHALMOLOGICA
(2023)
Article
Ophthalmology
Barbara Iaccheri, Giovanni Torroni, Alessio Cerquaglia, Marco Messina, Davide Tucci, Daniela Fruttini, Carlo Cagini, Tito Fiore
Summary: This study confirms the utility of warm compresses and artificial tears in the management of meibomian gland dysfunction (MGD), and investigates if the addition of topical cyclosporine A (CsA) improves outcomes. The results show significant improvement in OSDI, tear test, ocular surface evaluation, and clinical grading of MG at 6 months in both treatment groups. However, the addition of CsA shows significantly better results in IVCM evaluation compared to the group without CsA. IVCM is an effective tool for monitoring MGD treatments.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Tito Fiore, Marco Lupidi, Alessio Cerquaglia, Fabrizio Giansanti, Michele Reibaldi, Barbara Iaccheri, Davide Tucci, Marco Messina, Carlo Cagini
Summary: Retrospective analysis shows that OCT changes after acute postoperative endophthalmitis can be persistent or self-resolving, and seem to be related to the progression of infection/inflammation from the vitreous cavity to the inner and outer retina, rather than to the surgery.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Joao Pedro Marques, Rosa Pinheiro, Ana Luisa Carvalho, Miguel Raimundo, Mario Soares, Pedro Melo, Joaquim Murta, Jorge Saraiva, Rufino Silva
Summary: This study describes the genetic spectrum, retinal phenotypes, and pRNFL thickness in a cohort of Caucasian RPGR-mutation heterozygotes. The results show that clinically severe phenotypes are not uncommon among female carriers, and provide novel insights into pRNFL changes observed in RPGR heterozygotes that mimic what has been reported in male patients.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Eliane Luisa Esser, Julian Alexander Zimmermann, Jens Julian Storp, Nicole Eter, Natasa Mihailovic
Summary: The study aimed to evaluate the impact of hydroxychloroquine (HCQ) on ocular microvascular vessel density (VD) in patients with rheumatoid arthritis (RA). The results showed no evidence of VD reduction in RA patients, but those who had been using HCQ for a long time had a significantly reduced retinal thickness (RT).
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Medicine, General & Internal
Sonja K. Eilts, Johanna M. Pfeil, Broder Poschkamp, Tim U. Krohne, Nicole Eter, Teresa Barth, Rainer Guthoff, Wolf Lagreze, Milena Grundel, Marie-Christine Bruender, Martin Busch, Jayashree Kalpathy-Cramer, Michael F. Chiang, R. V. Paul Chan, Aaron S. Coyner, Susan Ostmo, J. Peter Campbell, Andreas Stahl
Summary: By analyzing the vascular severity score (VSS) of infants with retinopathy of prematurity (ROP), the study evaluated the regression and reactivation of ROP after anti-VEGF treatment and identified eyes at risk of ROP reactivation requiring retreatment.
Article
Ophthalmology
Jana Jiang, Daniel Boehringer, Claudia Auw-Haedrich, Philip Christian Maier, Teresa Barth, Nicole Eter, Matthias Fuest, Gerd Geerling, Ludwig M. Heindl, Martina Herwig-Carl, Christoph Hintschich, Katerina Hufendiek, Daniel Kampik, Wolfgang Lieb, Daniel Meller, Arthur Mueller, Norbert Pfeiffer, Matus Rehak, Marc Schargus, Berthold Seitz, Martin Spitzer, Andreas Stahl, Daniela Suesskind, Christian van Oterendorp, Felix Mathias Wagner, Henrike Westekemper, Focke Ziemssen, Thomas Reinhard
Summary: This study evaluates the standard of care in tertiary eye centres in Germany for the treatment of ocular surface squamous neoplasia or melanocytic tumours, focusing on the use of topical or subconjunctival interferon-α 2b. The results show that interferon-α 2b is the preferred second-line option for treating these tumours. However, the withdrawal from the market and supply shortages may have a profound impact on patient care and quality of life.
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
(2023)
Article
Ophthalmology
Sidra Zafar, Annette Walder, Salim Virani, Kristin Biggerstaff, Silvia Orengo-Nania, Jonathan Chang, Roomasa Channa
Summary: Intravitreal anti-VEGF injections are associated with a higher risk of systemic adverse events in patients with diabetes, according to this study.
JAMA OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Ricardo Machado Soares, Ana Luisa Carvalho, Silvia Simao, Celia Azevedo Soares, Miguel Raimundo, C. Henrique Alves, Antonio Francisco Ambrosio, Joaquim Murta, Jorge Saraiva, Rufino Silva, Joao Pedro Marques
Summary: This study aims to provide detailed information about the natural history, genetic landscape, and phenotypic spectrum of EYS-associated retinal degeneration (EYS-RD). The study identified 8 novel EYS variants and found a high frequency of atypical phenotypes. Patients with atypical RP had better best-corrected visual acuity (BCVA) and larger ellipsoid zone widths, indicating a better prognosis.
OPHTHALMOLOGY RETINA
(2023)
Article
Cell Biology
Xikun Han, Ines Lains, Jun Li, Jinglun Li, Yiheng Chen, Bing Yu, Qibin Qi, Eric Boerwinkle, Robert Kaplan, Bharat Thyagarajan, Martha Daviglus, Charlotte E. Joslin, Jianwen Cai, Marta Guasch-Ferre, Deirdre K. Tobias, Eric Rimm, Alberto Ascherio, Karen Costenbader, Elizabeth Karlson, Lorelei Mucci, A. Heather Eliassen, Oana Zeleznik, John Miller, Demetrios G. Vavvas, Ivana K. Kim, Rufino Silva, Joan Miller, Frank Hu, Walter Willett, Jessica Lasky-Su, Peter Kraft, J. Brent Richards, Stuart MacGregor, Deeba Husain, Liming Liang
Summary: Age-related macular degeneration (AMD) is a leading cause of blindness in older adults. In this study, we investigated the genetic components shared between metabolites and AMD, using multi-ethnic genetic and metabolomic data. Through our analysis, we identified 108 potential causal relationships between plasma metabolites and advanced AMD, particularly in lipid-related pathways. This study provides valuable insights into the understanding of AMD pathogenesis and its risk factors.
CELL REPORTS MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Magdalena Davidescu, Letizia Mezzasoma, Katia Fettucciari, Luisa Pascucci, Marilena Pariano, Alessandro Di Michele, Oxana Bereshchenko, Carlo Cagini, Barbara Cellini, Lanfranco Corazzi, Ilaria Bellezza, Lara Macchioni
Summary: Hydroquinone, a toxic agent found in cigarette smoke, can damage retinal pigmented epithelial cells by triggering oxidative stress and mitochondrial dysfunction. This study found that cardiolipin, a phospholipid in the inner mitochondrial membrane, is involved in the toxicity of hydroquinone. Hydroquinone exposure led to increased reactive oxygen species and decreased mitochondrial membrane potential, but cell viability was preserved. Hydroquinone induced cardiolipin translocation and increased mitophagy, and prolonged treatment caused cell death through caspase-1 and gasdermin-D activation. Cardiolipin-specific antioxidants counteracted the effects of hydroquinone, suggesting its role as a signaling molecule in mitochondrial function and cell death. The study proposes cardiolipin-targeting compounds as potential treatments for retinal diseases related to oxidative stress.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2023)
Article
Ophthalmology
Jose M. Ruiz-Moreno, Rosa Gutierrez-Bonet, Ashay Chandra, Kiran Kumar Vupparaboina, Jay Chhablani, Jorge Ruiz-Medrano
Summary: This study aimed to compare the efficacy of CVI and CT as biomarkers in acute CSCR. Analysis of 40 patients' eyes revealed that CVI may be a more specific and reliable biomarker, while CT did not meet the criteria for biomarker.
OPHTHALMIC RESEARCH
(2023)